Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Related Keywords

United States ,American ,Castle Biosciences ,Arthurg James ,Kari Kendra ,Iovance Biotherapeutics ,Genentech ,Department Of Oncologic Sciences ,Richardj Solove Research Institute ,Ohio State University Comprehensive Cancer Center ,American Society Of Clinical Oncology Annual Meeting ,Pfizer ,Compugen ,Novartis ,Cancer Hospital ,Cutaneous Oncology ,Moffitt Cancer Center ,Oncologic Sciences ,South Florida Morsani College ,Clinical Oncology Annual Meeting ,Instil Bio ,Nresectable Metastatic Desmoplastic Melanoma ,Pembrolizumab ,Aacr Annual Meeting ,Cutaneous Melanoma ,Swog S1512 Trial ,